Evaluation of Hypoxia by PET With F-Miso in Radiation Therapy of Prostate Cancer
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
With functional imaging development, it becomes possible to increase radiation dose to
radioresistant areas (located inside tumor volume) using radiotherapy dose-painting. This
strategy is particularly suitable for prostate cancer where tumor hypoxia plays a major role
in the resistance of these tumors to radiation.
In order to develop intratumoral hypoxia targeting by radiotherapy dose-painting areas, we
should characterize changes in hypoxia before treatment and during radiotherapy.
- If hypoxia does not change during radiotherapy, radiotherapy dose-painting strategy by
an "integrated" boost is performed.
- If hypoxia varied (increasing or incomplete regression), a "final" boost strategy of
radiotherapy dose-painting(IMRT, stereotactic brachytherapy or high dose rate) after a
first fractionated IMRT could be considered.
This study should show that PET imaging with fluoromisonidazole (18F-MISO) is an available
tool to physicians in assessing tumor hypoxia.
Phase:
Phase 2
Details
Lead Sponsor:
Institut Cancerologie de l'Ouest
Collaborators:
Cyclopharma IASON Gmbh, Feldkirchner strasse 4, 8054 Graz-Seiesberg AUSTRIA Poitiers University Hospital